SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with community chatter focused on a potential breakout and significant price movement. Bullish sentiment is fueled by expectations of strong earnings and guidance, and some are pointing to potential tailwinds like future rate cuts and crypto integration. The stock's ability to break through the $30 resistance level is a key point of discussion.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending amidst discussions about its new NFL partnership and an analyst report questioning the move, sparking debate about the company's direction. The community is also analyzing recent price action, pondering whether the stock is undervalued or if deeper issues are at play, while closely watching for potential catalysts.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as the company recently launched new AI chips aimed at competing with Nvidia and AMD in the data center market, generating significant buzz and a surge in stock price. Community discussions revolve around the potential impact of these chips, revenue projections, and whether Qualcomm can truly challenge the dominance of existing players. Some analysts express skepticism, citing the chips' specifications and disclosed customer base, while others highlight the company's shift towards AI infrastructure.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as investors weigh the potential impact of a new web browser from OpenAI, a possible competitor to Google Chrome. Despite the concerns, many community members view the dip as a buying opportunity, emphasizing Google's diverse portfolio and strong position in AI and cloud computing.  Additionally, some analysts have recently raised their price targets for the stock, citing positive advertising and cloud channel checks.

Trump For President

Trump Crypto is trending amid mixed community sentiment, with some users discussing potential pumps and scams while others express political opinions related to Trump. Bullish investors are anticipating gains, while bearish investors are pointing to the coin's performance since launch. The coin seems to be moving in response to triggers related to its namesake figure.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors react to the company's plans to cut up to 30,000 corporate jobs, with community members discussing the implications for the broader economy and the potential impact of AI and automation on the workforce. Some view the layoffs as a cost-cutting measure before earnings, while others speculate about a potential recession. Despite the concerns, some investors see the dip as a buying opportunity, drawing comparisons to past layoff announcements that preceded stock rallies.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to a significant volume spike and discussions around its potential for a parabolic move. Community members are closely watching for continuation and a possible short squeeze, citing a very low float and insider ownership. Some traders are also pointing to a recent revenue growth update as a potential catalyst.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending due to a sharp decline following the pause of its Phase 3 trials for nex-z after a patient experienced liver problems, leading to a significant stock drop. The community is debating whether this is an overreaction and a buying opportunity, or a justified re-pricing due to potential issues with its leading program. Technical analysis suggests a potential rebound around the $15 support level, while some analysts remain optimistic about risk-mitigation strategies.

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Campbell, CA.

Semler Scientific Inc

Semler Scientific is trending following news of its acquisition by Strive in an all-stock deal, which represents a significant premium for SMLR shareholders. The community is actively discussing the implications of the merger, particularly the fixed exchange ratio and potential arbitrage opportunities, with some expressing concerns about dilution. Bullish sentiment centers around the combined company's increased Bitcoin holdings and potential for a short squeeze.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending amid discussions of a potential short squeeze and excitement around the company's role in the AI revolution, particularly its fiber network and recent partnership. Community members are pointing to institutional ownership and insider buying as bullish signals, with some speculating about upcoming announcements and positive earnings. Overall, the conversation is centered on the company's AI-driven growth potential and its undervaluation in the market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus

Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Are Medical Stocks Lagging  Amneal Pharmaceuticals (AMRX) This Year?

Here is how Amneal Pharmaceuticals (AMRX) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Amneal Pharmaceuticals (AMRX) said on Tuesday that its generic equivalent of AbbVie's (ABBV) eyedrops received approval from the U.S. Food and Drug Administration.The company’s Bimatoprost ophthalmic solution 0.01% is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Receives-U-S--FDA-Approval-for-Bimatoprost-Ophthalmic-Solution-0-01/default.aspx">indicated</a> for reducing high eye pressure in patients with open-angle glaucoma or ocular hypertension. It is a generic equivalent of LUMIGAN 0.01%, whose design is a trademark of AbbVie’s Allergan.Shares of the company rose 5% in the pre-market session at the time of writing. On Stocktwits, the retail sentiment around <a href="https://stocktwits.com/symbol/AMRX">AMRX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.The New Jersey-headquartered company said the most common adverse reaction associated with the use of eyedrops is conjunctival hyperemia or redness of the eye. The company expects the solution to be a key growth driver for its Affordable Medicines portfolio.“As the prevalence of glaucoma continues to rise, particularly among the aging population, it is critical that patients and providers have affordable access to effective treatments such as bimatoprost. This represents our most recent complex new product approval this year…,” company executive Srinivas Kone said. Open-angle glaucoma is a progressive eye disease that involves optic nerve damage and vision loss due to high eye pressure.Earlier this month, the company also announced FDA approval for its sodium oxybate oral solution 500 mg/mL indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy. Narcolepsy is characterized by excessive daytime sleepiness, sudden sleep attacks, and cataplexy, a sudden loss of muscle control often triggered by emotions.AMRX stock is up by 26% this year and by about 17% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-says-updated-mnexspike-covid-shot-demonstrated-rbust-immune-response-in-study/chDhMlcR35J">Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Amneal Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops

Amneal’s bimatoprost ophthalmic solution 0.01% is indicated for the reduction of high eye pressure in patients with certain eye conditions.

Equity

Amneal’s bimatoprost ophthalmic solution 0.01% is indicated for the reduction of high eye pressure in patients with certain eye conditions.


Wall Street Analysts Think Amneal (AMRX) Could Surge 25.52%: Read This Before Placing a Bet

The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?

Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

AMRX
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AMRX News

AMRXAmneal Pharmaceuticals Inc - Ordinary Shares - Class A